Drugs / Biodesign Otologic graft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03904316 | Oct 2018 → Jul 2022 | tympanic membrane disorder | Henry Ford Health System | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biodesign Otologic graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03904316 ↗ |
| Modality | Other / unclassified | “Acellular matrix derived from porcine small intestine submucosa” NCT03904316 ↗ |